Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy

被引:42
作者
Abanades, Sergio [1 ,2 ]
van der Aart, Jasper [1 ]
Barletta, Julien A. R. [1 ]
Marzano, Carmine [1 ]
Searle, Graham E. [1 ]
Salinas, Cristian A. [1 ]
Ahmad, Javaad J. [1 ]
Reiley, Richard R. [1 ]
Pampols-Maso, Sabina [1 ]
Zamuner, Stefano [3 ]
Cunningham, Vincent J. [1 ]
Rabiner, Eugenii A. [1 ,2 ]
Laruelle, Marc A. [2 ,4 ]
Gunn, Roger N. [1 ,2 ,5 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Clin Imaging Ctr, GlaxoSmithKline, London W12 0NN, England
[2] Univ London Imperial Coll Sci Technol & Med, Div Neurosci & Mental Hlth, London W12 0NN, England
[3] GlaxoSmithKline Inc, Clin Pharmacol Modelling & Simulat, Verona, Italy
[4] GlaxoSmithKline Inc, Neurosci Ctr Excellence Drug Discovery, Harlow, Essex, England
[5] Univ Oxford, Dept Engn Sci, Oxford OX1 3PJ, England
关键词
drug occupancy; duloxetine; 5-HTT; mathematical modelling; positron emission tomography (PET); POSITRON-EMISSION-TOMOGRAPHY; SEROTONIN TRANSPORTER; DRUG DEVELOPMENT; IN-VITRO; DULOXETINE; PET; RECEPTOR; PERSPECTIVES; C-11-DASB; DESIGN;
D O I
10.1038/jcbfm.2010.175
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Positron emission tomography (PET) is used in drug development to assist dose selection and to establish the relationship between blood and tissue pharmacokinetics (PKs). We present a new biomathematical approach that allows prediction of repeat-dose (RD) brain target occupancy (TO) using occupancy data obtained after administration of a single dose (SD). A PET study incorporating a sequential adaptive design was conducted in 10 healthy male adults who underwent 4 PET scans with [C-11] DASB ([C-11]N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine): 1 at baseline, 2 after 20mg SD of the 5-hydroxytryptamine transporter (5-HTT) inhibitor duloxetine, and 1 after 4 days daily administration of 20mg duloxetine. An adaptive design was used to select optimal times after SD for measurement of occupancy. Both direct and indirect PK/TO models were fitted to the SD data to characterise the model parameters and then applied to a predicted RD duloxetine plasma time course to predict the 5-HTT occupancy after RD. Repeat-dose prediction from the indirect model (OC50 = 2.62 +/- 0.93 ng/mL) was significantly better (P < 0.05) than that from the direct model (OC50 = 2.29 +/- 1.11 ng/mL). This approach increases the value of SD occupancy studies that are performed as part of first time in human drug development programmes by providing an estimate of the dose required to achieve the desired TO at RD. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 944-952; doi:10.1038/jcbfm.2010.175; published online 13 October 2010
引用
收藏
页码:944 / 952
页数:9
相关论文
共 25 条
  • [1] Ariens EJ., 1964, MOL PHARM MODE ACTIO
  • [2] Beal SL., 1998, NONMEM Users Guide
  • [3] Pharmacokinetic-pharmacodynamic modelling: History and perspectives
    Csajka, Chantal
    Verotta, Davide
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (03) : 227 - 279
  • [4] Quantification in positron emission tomography for research in pharmacology and drug development
    Cunningham, VJ
    Gunn, RN
    Matthews, JC
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2004, 25 (07) : 643 - 646
  • [5] Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives
    Derendorf, H
    Meibohm, B
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (02) : 176 - 185
  • [6] POPED, a software for optimal experiment design in population kinetics
    Foracchia, M
    Hooker, A
    Vicini, P
    Ruggeri, A
    [J]. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2004, 74 (01) : 29 - 46
  • [7] Frankle WG, 2006, J NUCL MED, V47, P815
  • [8] Parametric imaging of ligand-receptor binding in PET using a simplified reference region model
    Gunn, RN
    Lammertsma, AA
    Hume, SP
    Cunningham, VJ
    [J]. NEUROIMAGE, 1997, 6 (04) : 279 - 287
  • [9] Simplified reference tissue model for PET receptor studies
    Lammertsma, AA
    Hume, SP
    [J]. NEUROIMAGE, 1996, 4 (03) : 153 - 158
  • [10] Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects
    Lantz, RJ
    Gillespie, TA
    Rash, TJ
    Kuo, F
    Skinner, M
    Kuan, HY
    Knadler, MP
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) : 1142 - 1150